Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rhenium-188 P 2045

Drug Profile

Rhenium-188 P 2045

Alternative Names: BAY-865284; NeoTide; P2045; Re-188 P 2045; Rh-188 P2045; Rhenium-188 P2045; Tozaride

Latest Information Update: 15 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Andarix Pharmaceuticals
  • Class Antineoplastics; Heavy metals; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Somatostatin receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Small cell lung cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 15 Apr 2019 Rhenium-188 P 2045 is still in phase I/II trials for Non-small cell lung cancer in USA (Andarix website, April 2019)
  • 15 Apr 2019 Rhenium-188 P 2045 is still in preclinical trials for pancreatic cancer in USA (Andarix website, April 2019)
  • 15 Apr 2019 Rhenium-188 P 2045 is still in phase I/II trials for Small-cell lung cancer in USA (Andarix website, April 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top